Journal of Diabetes and Its Complications
Volume 20, Issue 2 , Pages 98-104 , March 2006

Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients

Received 18 August 2004 ,Accepted 23 May 2005.

References 

  1. Banba N, Nakamura T, Matshumura M, Kuroda H, Hattori Y, Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney International. 2000;58:684–690
  2. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circulation Research. 1998;83:952–959
  3. Crouse JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, et al. Pravastatin, lipid, and atherosclerosis in the carotid arteries (PLAC-II). American Journal of Cardiology. 1995;75:455–459
  4. Davis MD. Natural evolution. In:  L'Esperance FA editors. Current diagnosis and management of chorioretinal diseases. St Louis: CV Mosby; 1974;p. 179–184
  5. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690–695
  6. Festa A, D'Agostino R, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, et al. The relation of body fat mass and distribution to markers of chronic inflammation. International Journal of Obesity. 2001;25:1407–1415
  7. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Molecular Cell. 1998;2:275–281
  8. Harley SL, Powell JT. Fibrinogen up-regulates the expression of monocyte chemoattractant protein 1 in human saphenous vein endothelial cells. Biochemical Journal. 1999;341:739–744
  9. Ihm CG, Park JK, Hong SP, Lee TW, Cho BS, Kim MJ, et al. A high glucose concentration stimulates the expression of monocyte chemotactic peptide-1 in human mesangial cells. Nephron. 1998;79:33–37
  10. Kawamori R, Yamasaki Y, Matsushima H, Nishizawa H, Nao K, Hougaku H, et al. Prevalence of carotid atherosclerosis in diabetic patients. Ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care. 1992;15:1290–1294
  11. Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS. Human endothelium as a source of multifunctional cytokines: Molecular regulation and possible role in human disease. Journal of Interferon & Cytokine Research. 1999;19:91–104
  12. Kumar AG, Ballantyne CM, Micheal LH, Kukielka GL, Youker KA, Lindsey ML, et al. Induction of monocyte chemoattractant protein-1 in the small veins of the ischemic and reperfused canine myocardium. Circulation. 1997;95:693–700
  13. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-medicated: Upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation. 2000;101:2889–2895
  14. Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirose T, Ishida T, et al. Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: Synergism with hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:115–120
  15. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. Journal of Clinical Investigation. 1991;88:1121–1127
  16. O'Leary DH, Polak JF, Kronmal RA, Kittner SJ, Bond MG, Wolfson SK, et al. Distribution and correlate of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke. 1992;23:1752–1760
  17. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effects of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165–2168
  18. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  19. Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini MP, et al. Fasting plasma leptin, tumor necrosis factor-α receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women. Diabetes Care. 2003;26:2883–2889
  20. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging. Circulation. 1986;74:1399–1406
  21. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis. 1999;147:213–225
  22. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New England Journal of Medicine. 1997;336:973–979
  23. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine. 2000;342:836–843
  24. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. Journal of the American Medical Association. 2001;285:2481–2485
  25. Robinson EA, Yoshimura T, Leonard EJ, Tanaka S, Griffin PR, Shabanowitz J, et al. Complete amino acid sequence of a human monocyte chemoattractant, a putative medicator of cellular immune reactions. Proceedings of the National Academy of Sciences of the United States of America. 1989;86:1850–1854
  26. Shyy YJ, Hsieh HJ, Usami S, Chien S. Fluid shear stress induces a biphasic response of human monocyte chemoattractant protein 1 gene expression in vascular endothelium. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:4678–4682
  27. Takeya M, Yoshimura T, Leonard EJ, Takahashi K. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Human Pathology. 1993;24:539–543
  28. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney International. 2000;58:1492–1499
  29. Yamashiro S, Kamohara H, Yoshimura T. MCP-1 is selectively expressed in the rate phase by cytokine-stimulated human neutrophils: TNF-alpha plays a role in maximal MCP-1 mRNA expression. Journal of Biological Chemistry. 2001;276:25096–25100
  30. Yerneni KK, Bai W, Khan BV, Medford RM, Natavajan R. Hyperglycemia-induced activation of nuclear transcription factorêB in vascular smooth muscle cells. Diabetes. 1999;48:855–864
  31. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proceedings of the National Academy of Sciences of the United States of America. 1991;88:5252–5256
  32. Yu H, Zeng Y, Hu J, Li C. Fluid shear stress induces the secretion of monocyte chemoattractant protein-1 in cultured human umbilical vein endothelial cells. Clinical Hemorheology and Microcirculation. 2002;26:199–207

PII: S1056-8727(05)00051-6

doi: 10.1016/j.jdiacomp.2005.05.008

Journal of Diabetes and Its Complications
Volume 20, Issue 2 , Pages 98-104 , March 2006

Article Tools

* Image Usage & Resolution